Novo Nordisk Bumped Up Its Forecast, but Wall Street Is Still Nervous
Novo Nordisk has raised its full-year sales and profit forecasts after reporting a strong second quarter. However, investors were…
-
-
Novo Nordisk Draws Contrarian Support Over Eli Lilly as GLP-1 Valuation Gap Widens
Investors are taking a fresh look at the top companies making weight-loss drugs. A recent panel on CNBC suggested…
-
Eli Lilly Launches Oral Weight-Loss Drug and Acquires Centessa Pharmaceuticals for $6.3 Billon
Eli Lilly, a leading pharmaceutical company, made two significant strategic initiatives to increase its market share. Foundayo, the company’s…
-
Wegovy Pill Triggers Oral Obesity Drug Race as Eli Lilly Advances Orforglipron Toward Approval
The new oral version of semaglutide has reached high prescription numbers since its recent release. A data firm called…
-
Eli Lilly’s Orforglipron Positions to Challenge Novo Nordisk’s Oral GLP-1 Lead
Eli Lilly is preparing to launch a new weight-loss pill called orforglipron. They expect the government to approve it…
-
The Battle for the Daily Weight Loss Pill: Novo Nordisk Faces Off Against Eli Lilly
Eli Lilly is eating into the injectable weight management market at a blistering pace. That leaves Novo Nordisk scrambling…
-
Novo Nordisk and Hims & Hers Reach Distribution Agreement for Wegovy and Ozempic, Ending Patent Litigation
Novo Nordisk and the health site Hims & Hers just signed a major deal. This new partnership lets people…
-
Wegovy Portfolio Update: Focus Shifts to Oral Pill as Injectable Sales Peak
Novo Nordisk has introduced a new oral version of its popular weight-loss drug, Wegovy. Many patients are used to…
